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INTRODUCTION 
Despite the recent advances in surgical techniques, chemotherapy (CTX) and 
radiotherapy (RT), treatment of locally advanced head and neck cancers arising in the 
nasal cavity, paranasal sinuses and temporal bone has been highly challenging in head 
and neck oncology. Because the advanced lesions often involve the skull base, treatment 
is technically challenging for both the radiation oncologists and surgeons because of the 
close proximity and relative radiosensitivity of adjacent critical structures including the 
orbit, central nervous system and the internal carotid artery. Obtaining sufficient 
surgical margins in this area of critical functional anatomy is difficult, with a risk of 
causing great morbidity to the patients. Oncological results of surgical treatment for 
cancers involving the cavernous sinus (CS) and/or brain tissues are quite poor with 
significant severe complications (1). 
Particle beams, such as proton and heavier ion beams, show an increase in energy 
deposition with a penetration depth of up to a sharp maximum at the end of their range 
to form the so-called Bragg peak. Almost no dose is deposited in the normal tissue beyond 
the Bragg peak with a sharp dose fall-off at the field borders, providing the precise dose 
localization compared with photon beams. In addition, this precise dose localization 
facilitates dose escalation without increasing toxicity in the surrounding normal tissues. 
From a biological aspect, protons have a higher linear energy transfer than photons, but 
their radiobiologic properties do not differ substantially from those of photons. However, 
heavier ions such as carbon ions not only have the favorable physical properties of 
protons but also have a superior biologic advantage in comparison with protons or 
photons. The biologic advantages of carbon ions over protons are expected to be most 
pronounced for radioresistant malignant tumors. 
On 1 April 2001, the Hyogo Ion Beam Medical Center (HIBMC) was opened as the 
world’s first facility to provide both proton and carbon ion RT. After ministerial approval 
was granted, regular practice was initiated in April 2003 for proton RT and in March 
2005 for carbon ion RT (2 –14). The purpose of this study was to determine the 
oncological outcomes and complications of patients with unresectable primary head and 
neck cancers invading the skull base treated with proton or carbon ion RT. 
 
 
PATIENTS AND METHODS 
Between April 2003 and December 2009, 441 patients with head and neck cancers were 
treated with particle RT at HIBMC. Two hundred and sixty-two patients were treated 
with proton RT, and 179 patients were treated with carbon ion radiotherapy. Fifty-seven 
of the 179 patients who had previously untreated locally advanced unresectable primary 
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head and neck cancers invading the skull base without lymph node metastasis or distant 
metastasis were retrospectively analyzed in this study. The extent of the tumor was 
assessed using magnetic resonance imaging (MRI) and computed tomography (CT). 
Patients were staged according to the 2002 American Joint Committee on Cancer staging 
system. Unresectability due to skull base invasion was determined as apparent direct 
invasion to the brain tissue, CS or carotid canal. 
Pathologic types were 25 adenoid cystic carcinomas (ACCs), 14 squamous cell 
carcinomas (SCCs), six olfactory neuroblastomas (ONBs), four adenocarcinomas (ADs), 
four malignant melanomas (MMs), three undifferentiated carcinomas (UDCs) and one 
osteosarcoma (OS). Primary sites were paranasal sinus in 39 patients, nasal cavity in six 
patients, nasopharynx in six patients, parapharyngeal space in two patients, parotid 
gland in two patients and external and middle ear in two patients. The patients consisted 
of 29 males and 28 females aged from 24 to 81 years with an average age of 55 years. 
Performance status was 0 in 11 patients, 1 in 44 patients and 2 in two patients. 
Among 47 patients treated with proton RT, 30 received 65.0 gray equivalent (GyE)/26 
fraction (fr), one received 70.0 GyE/28 fr and 16 received 70.2 GyE/26 fr. Ten patients 
were treated with carbon ion RT. Of the 10 patients, six received 57.6 GyE/16 fr, two 
received 60.8 GyE/16 fr and two received 70.2 GyE/26 fr. Optimal dose fractionation was 
determined for each patient based on discussion by several radiation oncologists. 
Particle RT was delivered daily at five per week, to the isodose encompassing the 
planning target volume (PTV). To protect the optic nerve, optic chiasm and spinal cord, 
doses were limited to 52, 52 and 48 GyE, respectively. The tumors were treated with a 5 
mm field margin as the clinical target volume and 3 mm (carbon ion beams) or 5 mm 
(proton beams) field margins as the PTV. Choices of beam were determined to obtain the 
optimal dose distribution to the targeted lesion and maximum reduction of dose 
deposition in non-targeted critical tissues, such as optic nerves, optic chiasm, eye balls, 
brain, brain stem and spinal cord. 
All patients were followed up at least 12 months or until death. The median follow-up 
period was 32.1 months, ranging from 6.4 to 80.4 months. Response was classified 
according to Response Evaluation Criteria in Solid Tumor. Acute and late toxicities were 
scored according to the National Cancer Institute Common Terminology Criteria for 
Adverse Event v4.0. Survival rates and local progression-free rates were calculated using 
the Kaplan–Meier method. 
 
 
RESULTS 
Characteristics of the patients treated with proton ions are summarized in Table 1. In 
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the patients treated with proton RT, a complete response (CR) and partial response (PR) 
were achieved in two patients and 21 patients, respectively. In 24 patients, the response 
was judged as stable disease (SD). Progression of disease (PD) was not observed. During 
the follow-up periods, local recurrence or progression of local disease was observed in one 
patient (50%) in the CR group, nine patients (43%) in the PR group and 12 patients (50%) 
in the SD group. Regional lymph node metastasis was observed in two patients (100%) in 
the CR group and three patients (13%) in the SD group. No regional lymph node 
metastasis was observed in the PR group. Distant metastasis was observed in two 
patients (100%) in the CR group, eight patients (38%) in the PR group and 10 patients 
(42%) in the SD group. Representative pretreatment and posttreatment imagings and 
dose distribution of proton radiotherapy are shown in Fig. 1. Mucositis and dermatitis 
are seen as acute toxicity, but none of the patients developed Grade 4 or 5 acute toxicity. 
In terms of late toxicity, the most common toxicity was visual disorder. Grades 2, 3 and 4 
visual disorders were observed in three, four and two patients, respectively. Grades 3 and 
4 nervous system disorders were observed in one patient each. Details are seen in Table 2. 
No other severe late complication was observed. 
In the patients treated with carbon ion RT, CR and PR were achieved in one and four 
patients, respectively. In five patients, the response was judged as SD, and PD was not 
observed. During the follow-up periods, local recurrence or progression of local disease 
was observed in three patients. Regional lymph node metastasis and distant metastasis 
were observed in two and four patients, respectively. Patient characteristics are listed in 
Table 3, and representative pretreatment and posttreatment imagings and dose 
distribution of carbon ion RT are shown in Fig. 2. Grade 3 mucositis and dermatitis are 
seen as acute toxicity, but none of the patients developed Grade 4 or 5 acute toxicity. The 
most common late toxicity was visual disorder. Grades 2 and 3 visual disorder was 
observed in four patients (three optic nerve disorders and one retinal vascular disorder) 
and one patient (optic nerve disorder), respectively. Grade 3 central nervous system 
necrosis was observed in one patient. Grade 2 osteonecrosis of the jaw and Grade 2 
middle ear inflammation were observed in one and two patients, respectively. Details are 
seen in Table 4. 
 The actual 3-year overall survival rate and local progression-free rate of all the patients 
were 60 and 55%, respectively (Fig. 3). According to the pathologic types, the actual 
3-year overall survival rates were 80% for ACC, 44% for SCC, 75% for ONB, 0% for AD 
and 38% for MM. Actual 3-year local progression-free rate was 63% for ACC, 28% for SCC, 
83% for ONB, 50% for AD (2-year) and 0% for MM(Table 5). 
According to primary site, the actual 3-year survival rate was 100% for nasopharynx, 
57% for maxillary sinus, 38% for ethmoid sinus, 63% for sphenoid sinus, 50% for frontal 
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sinus, 100% for nasal cavity, 0% for external and middle ear, 100% for parapharyngeal 
space and 50% for parotid gland (Fig. 3). The 3-year local progression-free rate was 83% 
for nasopharynx, 53% for maxillary sinus, 42% for ethmoid sinus, 63% for sphenoid sinus, 
50% for frontal sinus (2-year), 83% for nasal cavity, 0% for external and middle ear, 50% 
for parapharyngeal space and 0% for parotid gland (Table 6). 
Distant metastasis developed in 13 of 25 patients (52%) with ACC, two of 14 patients 
(14%) with SCC, one of six patients (17%) with ONB, two of four patients (50%) with AD, 
three of four patients (75%) with MM, one of three patients (33%) with UDC and one of 
one patient (100%) with OS. Regional lymph node metastasis developed in one patient 
with ACC and one with ONB, respectively, and one patient with both SCC and UDC. 
In terms of extent of the tumor, the actual 3-year overall survival rate was 45% in the 
patients with anterior skull base invasion (n = 23), 64% in the patients with middle skull 
base invasion (n = 11), 83% in the patients with CS invasion (n = 12) and 58% in the 
patients with CS and middle skull base invasion (n = 11). The 3-year local 
progression-free rate was 52% in the patients with anterior skull base invasion, 50% in 
the patients with middle skull base invasion, 62% in the patients with CS invasion, and 
61% in the patients with CS and middle skull base invasion. 
From the point of initial response to the particle therapy, the actual 3-year overall 
survival rate was 50% for the CR group, 70% for the PR group and 55% for the SD group. 
There was no statistical difference in the 3-year local progression-free rate between the 
CR (33%) and the PR groups (49%). The 3-year local progression-free rate was 33% for 
the CR group, 49% for the PR group and 61% for the SD group. There was no statistical 
significance in the actual 3-year survival rates or local progression-free survival rates in 
terms of the initial response. 
 
 
DISCUSSION 
According to the international collaborative study, craniofacial resection for malignant 
tumors of the skull base has 4.7% of the overall mortality rate and 36.3% of the 
complication rate, with 56% of the 5-year overall survival rate (1). Although malignant 
lesions involving CS, internal carotid artery or brain tissue can be technically resectable, 
this surgical procedure leads to disappointing oncological outcomes with great morbidity 
and mortality rates as well as poor functional results (15). Thus, cancers involving these 
lesions have been considered as unresectable from a practical standpoint. However, the 
reported oncological outcomes of conventional RT are also poor even in combination with 
CTX (16, 17) (Table 7). 
 Particle RT offers physical advantages over the conventional photon RT, which means 
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that improved dose distribution permits dose escalation within the target and optimal 
sparing of normal tissue (18). As expected, Zenda et al. (19) reported favorable outcome 
for patients with unresectable malignancies of the nasal cavity and paranasal sinuses 
treated with definitive proton RT. The 3-year overall survival rate was 58.0%. In this 
series, we obtained similar or better oncological results. The patients with far advanced 
tumors completed proton or carbon ion RT without fatal adverse events. Most frequent 
late toxicities were related to visual impairment. However, these were mainly observed 
in the diseased side, where exenteration of the orbital content cannot be avoided if 
surgical treatment is adopted. These results are substantially better than those reported 
previously for photon RT, suggesting that definitive proton RT may be a promising 
treatment option for patients who are not candidates for surgery. 
Moreover, favorable local control and survival rates of the patients with ACC (17), SCC 
(20) and ONB (21) invading the skull base were reported, suggesting the potential 
advantage of proton RT over conventional RT, especially for locally advanced disease 
with intracranial invasion (21). Because these oncological outcomes are not inferior to 
those of surgical treatment involving the craniofacial approach (22–24), definitive proton 
RT may be a promising treatment option for patients with not only unresectable but also 
resectable head and neck cancers invading the skull base (Table 7). 
In conventional RT with or without CTX, initial response was considered as a 
significant factor to predict therapeutic effect. However, interestingly, in the present 
study, there was no significant difference in the local progression-free and survival rates 
according to the initial response, in accordance with the report of Zenda et al. CR or PR 
was not necessarily required to obtain long-term local progression-free survival. Patients 
with long survival often show the persistence of the tumor on CT or MRI after proton RT 
(19). 
From the pathological oncological point of view, in this series, local progression-free 
rates and actual survival rates of the patients with ACC (14) and ONB (21) are favorable 
in comparison with other pathologies, in accordance with previous reports. Because these 
pathologies are relatively slow-growing, long-term follow-up is required to determine the 
significance. However, these results further support that ion beam therapy has its role in 
the treatment of ACC and ONB invading the skull base. However, slow-growing 
malignancies, such as ACC and ONB, most likely have microscopic metastases, as shown 
in our series. Hence, local treatment alone is insufficient for radical cure. Treatment 
strategies such as CTX and targeted therapy, for distant metastasis, should be 
considered for complete cure. 
On the other hand, local progression-free rates of the patients with SCC, MM and AD 
are unsatisfactory. Because most of the patients (82%) in the present series were treated 
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with proton RT, these results suggest that proton RT alone is not enough for such 
aggressive cancers. Combination with induction or concomitant CTX might be considered 
if proton RT is applied. The other option is carbon ion RT, which can be administered at 
our facility. Ramaekers et al. (25) reported from a systemic review and meta-analysis 
that carbon ion RT resulted in a statistically significant increase in the 5-year overall 
survival compared with conventional photon therapy for mucosal MM. Mizoe et al. 
reported that the outcome of carbon ion RT showed a specific effectiveness in local control 
of non-SCC, such as ACC (n = 9) and MM (n = 5). Five-year local control rates were 50 
and 100%, respectively (26). In the beginning, considering the high relative biological 
effectiveness of carbon ions, we hesitated to use carbon ion RT for cases with invasion of 
the skull base, which was exposed extensively in the brain. However, with experience, we 
found that late adverse events of carbon ion RT are acceptable with respect to such a far 
advanced malignant tumor invading the skull base, as shown in this study. Ever since 
ministerial approval was granted in 2005, we have made both proton and carbon ion 
treatment plans, and have selected the modality with better dose distribution at our 
daily conference. Thus, recently, we have been preferably using carbon ion RT for head 
and neck malignancies. Although the number of patients is limited, the oncological 
results are promising. 
 
 
CONCLUSIONS 
Particle RT is highly effective in the local control of unresectable locally advanced head 
and neck cancers with skull base invasion. Satisfactory oncological results were obtained 
for ONB and ACC. Although the follow-up period is still limited, acute and late toxicities 
were at acceptable levels except for optic disturbance. On the other hand, particle RT 
alone might be insufficient as a curative treatment against high-grade malignant tumors 
such as SCC, UDC and MM invading the skull base. Currently, we are planning a 
randomized clinical trial to compare the effects of proton RT and carbon ion RT for head 
and neck cancers. Concurrent or sequential CTX or/and molecular-targeted drugs in 
combination with particle RT also should be considered to develop an optimal strategy 
using particle RT for head and neck cancers. 
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Table 1. Patient characteristics (proton) 
Item No. of 
patients 
 Item No. of 
patients 
Age 26  Primary site  
  <60 years old 21    Paranasal sinus 33 
  >60 years old     Nasopharynx  5 
Gender     Nasal cavity  4 
  M 25    Parotid gland  2 
  F 22    External/middle ear  2 
Pathological types     Parapharyngeal space  1 
  ACC 22  Extent of tumor  
  SCC 13    Anterior skull base 19 
  ONB 4    Middle skull base 11 
  AD  3    Cavernous sinus 10 
  MM 2    Middle skull base 
  + cavernous sinus 
 7 
  UDC  3    
 
ACC, adenoid cystic carcinoma; SCC, squamous cell carcinoma; ONB, olfactory 
neuroblastoma; AD, adenocarcinoma; MM, malignant melanoma; UDC, undifferentiated 
carcinoma 
 
 
Table 2. Late toxicities (proton) 
Toxicity No. of patients 
 Grade 2 Grade 3 Grade 4 Grade 5 
Optic nerve disorder 2 3 2 - 
Cataract - 1 - - 
Extraocular muscle paralysis 1 - - - 
Edema cerebral - - 1 - 
Meningismus - 1 - - 
Pharyngeal mucositis - 1 - - 
Hearing impaired - 1 - - 
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Table 4. Late toxicities (carbon) 
Toxicity No. of patients 
 Grade 2 Grade 3 Grade 4 Grade 5 
Optic nerve disorder 3 1 - - 
Retinal vascular disorder 1 - - - 
Central nervous system necrosis - 1 - - 
Osteonecrosis of jaw 1 - - - 
Middle ear inflammation 2 - - - 
 
 
Table 5. Survival and local progression-free rates according to the pathological types 
Pathological 
types 
No. of 
patients 
Three-year 
survival rate (%) 
Three-year local 
progression-free rate (%) 
ACC 25 80 63 
SCC 14 44 28 
ONB  6 75 83 
AD  4  0 50 
MM  4 38  0 
UDC  3  0 67 
OS  1  0  0 
 
 
Table 6. Survival and local progression-free rates according to the primary site 
Primary site No. of 
patients 
Three-year 
survival rate (%) 
Three-year local 
progression-free rate (%) 
Nasopharynx  6 100 83 
Maxillary sinus 12 57 53 
Ethmoid sinus 17 38 42 
Sphenoid sinus  8  63 63 
Frontal sinus  2 50 50 
Nasal cavity  6 100 83 
External/middle 
ear 
 2   0  0 
Parapharyngeal 
space 
 2 100 50 
Parotid gland  2  50  0 
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Figure 3. Overall survival and local progression-free rates of all cases. 
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n
) 
A
C
C
, 
a
d
e
n
o
id
 c
y
st
ic
 c
a
rc
in
o
m
a
; 
O
N
B
, 
o
lf
a
ct
o
ry
 n
e
u
ro
b
la
st
o
m
a
; 
M
M
, 
m
a
li
g
n
a
n
t 
m
e
la
n
o
m
a
; 
S
C
C
, 
sq
u
a
m
o
u
s 
ce
ll
  
ca
rc
in
o
m
a
; 
A
D
, 
a
d
e
n
o
ca
rc
in
o
m
a
; 
S
, 
si
n
u
s;
 C
S
, 
ca
v
e
rn
o
u
s 
si
n
u
s;
 M
F
, 
m
id
d
le
 f
o
ss
a
; 
A
F
, 
a
n
te
ri
o
r 
fo
ss
a
; 
fr
, 
fr
a
ct
io
n
; 
P
R
, 
p
a
rt
ic
a
l 
re
sp
o
n
se
; 
S
D
, 
st
a
b
le
 d
is
e
a
se
; 
C
R
, 
co
m
p
le
te
 r
e
sp
o
n
se
; 
m
o
, 
m
o
n
th
s;
 D
is
t,
 d
is
ta
n
t 
re
cu
rr
e
n
ce
; 
D
W
D
, 
d
ie
d
 w
it
h
 d
is
e
a
se
; 
N
E
D
, 
n
o
 e
v
id
e
n
ce
 
o
f 
d
is
e
a
se
; 
A
W
D
, 
a
li
v
e
 w
it
h
 d
is
e
a
se
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A
u
th
o
rs
 
Y
e
a
r 
P
ri
m
a
ry
 S
it
e
 
M
a
in
 m
o
d
a
li
ty
 
N
o
. 
o
f 
p
a
ti
e
n
ts
 
S
u
rv
iv
a
l 
R
a
te
 (
%
) 
N
ib
u
 e
t 
a
. 
(1
5
) 
1
9
9
8
 
H
e
a
d
 a
n
d
 n
e
ck
 
S
k
u
ll
 b
a
se
 s
u
rg
e
ry
 
2
9
 
5
4
%
 (
5
 y
e
a
rs
) 
S
ch
u
lz
-E
rt
n
e
r 
e
t 
a
l.
 
(1
7
) 
2
0
0
3
 
H
e
a
d
 a
n
d
 n
e
ck
 (
A
C
C
) 
P
ro
to
n
 +
 c
a
rb
o
n
 
1
6
 
8
3
%
 (
3
 y
e
a
rs
) 
D
ia
z
 e
t 
a
l.
 (
2
2
) 
2
0
0
5
 
N
a
sa
l 
ca
v
it
y
 (
O
N
B
) 
S
k
u
ll
 b
a
se
 s
u
rg
e
ry
 
3
0
 
8
9
%
 (
5
 y
e
a
rs
) 
G
a
n
ly
 e
t 
a
l.
 (
1
) 
2
0
0
6
 
H
e
a
d
 a
n
d
 n
e
ck
 
S
k
u
ll
 b
a
se
 s
u
rg
e
ry
 
5
3
 
2
8
%
 (
3
 y
e
a
rs
) 
N
is
h
im
u
ra
 e
t 
a
l.
 (
2
1
) 
2
0
0
7
 
N
a
sa
l 
ca
v
it
y
 (
O
N
B
) 
 
P
ro
to
n
 
1
4
 
9
3
%
 (
5
 y
e
a
rs
) 
H
o
p
p
e
 e
t 
a
l.
 (
1
6
) 
2
0
0
8
 
P
a
ra
n
a
sa
l 
si
n
u
s 
(u
n
re
se
ct
a
b
le
) 
R
T
 w
/w
o
 C
T
X
 
3
8
 
1
5
%
 (
5
 y
e
a
rs
) 
Z
e
n
d
a
 e
t 
a
l.
 (
1
9
) 
2
0
1
0
 
P
a
ra
n
a
sa
l 
si
n
u
s 
P
ro
to
n
 
1
4
 
5
8
%
 (
3
 y
e
a
rs
) 
P
re
se
n
t 
st
u
d
y
 
2
0
1
4
 
H
e
a
d
 a
n
d
 n
e
ck
 
P
ro
to
n
/c
a
rb
o
n
 
5
8
 
6
1
%
 (
3
 y
e
a
rs
) 
T
a
b
le
 7
. 
S
u
rv
iv
a
l 
ra
te
s 
o
f 
p
u
b
li
sh
e
d
 c
a
se
s 
R
T
, 
ra
d
io
th
e
ra
p
y
; 
C
T
X
, 
ch
e
m
o
th
e
ra
p
y
; 
w
/w
o
, 
w
it
h
 o
r 
w
it
h
o
u
t.
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F
ig
u
re
 1
. 
P
ro
to
n
 r
a
d
io
th
e
ra
p
y
 (
R
T
).
 A
 5
5
-y
e
a
r-
o
ld
 f
e
m
a
le
 p
a
ti
e
n
t 
w
it
h
 a
d
e
n
o
id
 c
y
st
ic
 c
a
rc
in
o
m
a
 (
A
C
C
) 
in
v
a
d
in
g
 t
h
e
 c
a
v
e
rn
o
u
s
 
si
n
u
s 
(C
S
).
 P
R
 w
a
s 
o
b
ta
in
e
d
 b
y
 p
ro
to
n
 R
T
. 
S
h
e
 h
a
s 
b
e
e
n
 a
li
v
e
 w
it
h
o
u
t 
d
is
e
a
se
 f
o
r 
>
8
0
 m
o
n
th
s.
 (
a
) 
P
re
tr
e
a
tm
e
n
t 
G
d
-e
n
h
a
n
ce
d
 
T
1
-w
e
ig
h
te
d
 m
a
g
n
e
ti
c 
re
so
n
a
n
ce
 i
m
a
g
in
g
 (
M
R
I)
, 
(b
) 
b
e
a
m
 a
rr
a
n
g
e
m
e
n
t 
a
n
d
 (
c)
 T
2
-w
e
ig
h
te
d
 M
R
I 
3
6
 m
o
n
th
s 
a
ft
e
r 
p
ro
to
n
 R
T
. 
(a
) 
(b
) 
(c
) 
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F
ig
u
re
 2
. 
C
a
rb
o
n
 i
o
n
 R
T
. 
A
 5
9
-y
e
a
r-
o
ld
 f
e
m
a
le
 w
it
h
 n
a
so
p
h
a
ry
n
g
e
a
l 
A
C
C
 i
n
v
a
d
in
g
 t
h
e
 C
S
 a
n
d
 m
id
d
le
 c
a
rn
ia
l 
fo
ss
a
. 
P
R
 w
a
s 
o
b
ta
in
e
d
  
B
y
 c
a
rb
o
n
 i
o
n
 R
T
. 
S
h
e
 h
a
s 
b
e
e
n
 a
li
v
e
 w
it
h
o
u
t 
d
is
e
a
se
 f
o
r 
>
3
6
 m
o
n
th
s.
 (
a
) 
P
re
tr
e
a
tm
e
n
t 
G
d
-e
n
h
a
n
ce
d
 T
1
-w
e
ig
h
te
d
 M
R
I,
 (
b
) 
T
2
-w
e
ig
h
te
d
 
M
R
I 
3
6
 m
o
n
th
s 
a
ft
e
r 
ca
rb
o
n
 i
o
n
 R
T
 a
n
d
 (
c)
 b
e
a
m
 a
rr
a
n
g
e
m
e
n
t.
 
(a
) 
(b
) 
(c
) 
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